Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

Fig. 2

CD16 expression of CD11b+CD16+myeloid cells related to pathological features of CRC patients with capecitabine therapy. CRC patients receiving capecitabine therapy were divided into different groups according to their CEA or CA199 level (n = 20 in CEA-high (CEA > 5 ng) group and n = 114 in CEA-low (CEA ≤ 5 ng) group, n = 18 in CA199-high (CA199 > 27 ng) group and n = 116 in CA199-low (CA199 ≤ 27 ng) group). CD16 MFI of CD11b+CD16+myeloid cells in CRC patients acquired from flow cytometry analysis was compared between different groups. Mean ± SEM, **P<0.01, ***P<0.001 by t tests (a, b)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us